

Leading R&D Efficiency & Accelerating Innovation – Building BRIDGES



Forward-looking statements

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Note:

The 2015 and 2016 results are not fully comparable. The difference stems mainly from the acquisition of Evotec (France) SAS, effective 01 April 2015. While the results of Evotec (France) SAS are fully included in the accompanying consolidated income statement for the first nine months of 2016, they were not fully included in the comparable period of the previous year. In addition, effective 09 December 2015, Evotec acquired 51% of the shares in Panion Ltd., London, UK. This acquisition has been fully consolidated since that date. The accounting policies used to prepare interim information are the same as those used to prepare the audited consolidated financial statements for the year ended 31 December 2015.

Change in presentation:


The presented financial statements include a change in presentation in the first nine months of 2015 and 2016. From 01 January 2016 onwards, amortisation of intangible assets are no longer presented in a separate line in the consolidated income statement but are allocated to the relating cost lines in the income statement. The prior-year period was changed accordingly resulting in higher costs of revenue (€ 2.2 m).

Welcome

The Management Team



Werner Lanthaler, CEO¹⁾



Enno Spillner, CFO¹⁾



Mario Polywka, COO¹⁾



Cord Dohrmann, CSO¹⁾


Agenda

Highlights 9M 2016

EVT Execute

EVT Innovate

Financial performance and outlook



The leading innovation efficient discovery platform

EVT Execute & EVT Innovate – The business model



Strong performance and new ways for innovation

First nine months of 2016 – State of play

EVT Execute

- Important milestone achievements
- New long-term strategic drug discovery alliances
- Continued good progress of operations in Toulouse
- Continued expansion of existing drug discovery platforms
- First Phase I clinical start for the treatment of endometriosis with Bayer

EVT Innovate

- New multi-target alliance with Bayer in kidney diseases
- First research collaboration under French Academic Bridge with Inserm
- Acceleration of Target*NASH* programme
- Partnership with *ex scientia* to develop bispecific small molecule therapeutics
- Company formation of Topas Therapeutics
- Participation in Series A funding of Carrick Therapeutics
- **LAB282: BRIDGE** partnership with Oxford University, OSI and OUI (after period-end)

Strong growth trend continues

Financial highlights first nine months 2016 & Guidance 2016

Strong financial performance

- **Group revenues up 37% to € 120.6 m** (9M 2015: € 88.2 m)
 - EVT Execute revenues up 36%
 - EVT Innovate revenues up 26%
- **Adjusted Group EBITDA¹⁾ at € 30.6 m**
- **Net income at € 11.4 m**
- R&D expenses of € 12.8 m
- **Strong liquidity position of € 120.0 m²⁾**
 - Significant reduction of loans

Confirmation of updated guidance 2016

- More than 15% revenue growth excluding milestones, upfronts and licences
- **Adjusted Group EBITDA¹⁾ expected to more than double³⁾ compared to 2015** (2015: € 8.7 m)
- R&D expenses of approx. € 20 m
- Similar level of liquidity⁴⁾ compared to 2015
- Capex investments up to € 10 m

¹⁾ Before contingent considerations and excluding impairments on other intangible and tangible assets and goodwill as well as the total non-operating result


²⁾ Year-to-date 2016, short and long-term debt was reduced by € 8.1 m.

³⁾ On 19 July 2016, Evotec raised its profitability guidance mainly as a result of an increased margin contribution and a positive outlook for the remainder of the year.

⁴⁾ Excluding any potential cash outflow for M&A or similar transactions


Proposed acquisition of Cyprotex follows strategy

Strategy overview



Our “Sweet spot”

Generating the Pre-clinical Development Candidate (PDC)



Acquisition of Cyprotex expected to close still 2016

Summary and rationale of acquisition of Cyprotex

- World leader in pre-clinical ADME-Tox and DMPK testing¹⁾
 - 136 employees operating from 4 sites in the UK and USA
 - H1 2016 revenues of £ 8.73 m (€ 9.78 m^{**}); underlying EBITDA of £ 2.34 m (€ 2.62 m^{**})
 - Listed on UK AIM market
- Strong addition to Evotec's drug discovery platform
 - Strengthens EVT Execute stand-alone capabilities
 - Early screening and predictive ADME accelerates early decision making in integrated drug discovery projects
- Offer: Issued share capital and funding of all existing debt of Cyprotex PLC for approx. £ 55.36 m (€ 62.0 m^{**}) paid in cash
 - Offer of 1.60 £/share represents a 9.4% premium to VWAP of past 30 trading days
 - >50% Cyprotex shareholder irrevocables in place; intention to implement and secure transaction by a scheme of arrangement
- Full financial commitment for acquisition covered through Evotec's cash on balance sheet
 - Acquisition adds high-quality revenue and accretive EBITDA
 - If accepted by >75% of shareholders, deal should close by end of 2016



#RESEARCHNEVERSTOPS

NEWS RELEASE, 26 OCTOBER 2016

EVOTEC ANNOUNCES ITS INTENT TO ACQUIRE CYPROTEX PLC

- Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec's leadership in drug discovery
- Evotec will pay approximately £ 55.36 m (€ 62.00 m) in cash for the full share capital of Cyprotex and funding of all existing debt of the AIM-listed company
- Proposed acquisition, unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016

Hamburg, Germany, 26 October 2016:

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has made an offer to acquire Cyprotex PLC ("Cyprotex", AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Cyprotex serves the industry's increasing requirement for earlier drug screening, regulatory requirements and reducing the reliance on animal testing.

The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Evotec will pay approximately £ 55.36 m (€ 62.00 m; £/€ exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all existing company debt. The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec's revenues and be accretive to Evotec's 2017 EBITDA.

Cyprotex is the world's largest contract research organisation specialising in pre-clinical ADME-Tox and DMPK serving the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, was founded in 1999 and is publicly traded on AIM (CRX). It has 136 employees working from sites at Macclesfield and Alderley Park, both of which are located near Manchester in the UK, and at

For further information, please contact: Gabriele Hansen VP, Corporate Communications & Investor Relations, gabriele.hansen@evotec.com, T. +49 (0)40.360 81-255, F. +49 (0)40.360 81-333, www.evotec.com


Agenda

Highlights 9M 2016

EVT Execute

EVT Innovate

Financial performance and outlook




Strong growth in EVT Execute

EVT Execute – 9M 2016 versus prior-year period

Revenues (in € m)

Adjusted EBITDA¹⁾ (in € m)



- Increase in revenues attributable to growth in the base business, milestone achievements and three full quarters of Sanofi contribution
- Significant upswing of adjusted EBITDA mainly due to the strong growth in revenues and milestone payments
- 9M 2016 includes € 23.9 m of intersegment revenues

Most comprehensive platform in the industry

EVT Execute – Highlights first nine months of 2016




- Milestone achievements with Bayer, BI and Padlock
- Extension of drug discovery alliances (Genentech, Janssen Pharmaceutica NV)
- New long-term strategic drug discovery alliances (C4X Discovery, Antibiotic Research UK, UCB)
- New licences enhancing Evotec's platform (Trianni, CRISPR)
- Compound management gaining momentum (Pierre Fabre, UCB)
- Phase I clinical start in endometriosis in Bayer alliance
- Offer to acquire Cyprotex PLC (after period-end)

Integration of additional capacity works very well

Progress update Evotec (France)


- Evotec (France) – 18-month retrospective
 - Complex integration successfully ongoing
 - Evotec is now fully independent and operational on site in Toulouse and increased headcount by >30% since April 2015
 - Evotec fulfilled its commitment to further develop and sustain activity and employment on site in Toulouse
- Innovative partnerships, also with third parties
 - Pipeline-building partnership (e.g. partnered Target X initiatives)
 - Outsourcing partnerships (Sanofi, UCB, Pierre Fabre, Institut Claudius Regaud, ...)




Well-balanced global customer mix

EVT Execute – Selected customer and revenue metrics


Revenues by customer segment ytd 2016¹⁾ (in %)



Customer type ytd 2016¹⁾ (in %)



Revenues by region ytd 2016¹⁾ (in %)



Outlook 2016

EVT Execute – Expected key milestones 2016

- New long-term deals with large and mid-sized Pharma



- Expansion of foundations and biotech network in USA/EU



- New performance-based integrated technology/disease alliance



- Milestones from existing alliances




Agenda

Highlights 9M 2016

EVT Execute

EVT Innovate


Financial performance and outlook




Strong revenue growth and focused R&D expenses

EVT Innovate – 9M 2016 versus prior-year period


Revenues (in € m)



Adjusted EBITDA¹⁾ (in € m)



R&D expenses (in € m)




























- Revenue growth of 26% and improved adjusted EBITDA resulting from new partnerships signed in 2015
- No material change in R&D expenses
- Full impairment of EVT100 series (€ 1.4 m)²⁾

¹⁾ Adjusted for changes in contingent considerations

²⁾ In Q1 2016, Evotec was informed by Janssen Pharmaceuticals, Inc. that Janssen intends to phase out the licence agreement regarding NMDA antagonist with effect from August 2016.

Constantly growing pipeline of co-owned product opportunities – more than 70

Partnership portfolio


| | Molecule | Therapeutic Area/Indication | Partner | Discovery | Pre-clinical | Phase I | Phase II | Phase III | |
|--------------|----------------------|---|--|----------------|--------------|---------|----------|-----------|-----|
| Clinical | EVT302 ¹⁾ | CNS – Alzheimer's disease |  | [Progress bar] | | | | | ✗ |
| | EVT201 | CNS – Insomnia |  | [Progress bar] | | | | | |
| | EVT100 ¹⁾ | CNS – Depression |  | [Progress bar] | | | | | ✗ |
| | EVT401 | Immunology & Inflammation |  | [Progress bar] | | | | | |
| | ND ²⁾ | Oncology |  | [Progress bar] | | | | | |
| | ND ²⁾ | Oncology |  | [Progress bar] | | | | | |
| | Various | Women's health – Endometriosis |  | [Progress bar] | | | | | |
| Pre-clinical | ND ²⁾ | CNS – Pain |  | [Progress bar] | | | | | |
| | ND ²⁾ | Immunology & Inflammation |  | [Progress bar] | | | | | |
| | ND ²⁾ | Oncology |  | [Progress bar] | | | | | |
| | EVT770 | Metabolic – Diabetes (type 2/1) |  | [Progress bar] | | | | | |
| | ND ²⁾ | Respiratory |  | [Progress bar] | | | | | |
| | ND ²⁾ | Immunology & Inflammation |  | [Progress bar] | | | | | |
| | EVT801 | Oncology |  | [Progress bar] | | | | | |
| | EVT701 | Oncology |  | [Progress bar] | | | | | |
| | EVT601 | Oncology |  | [Progress bar] | | | | | |
| Discovery | ND ²⁾ | Nephrology |  | [Progress bar] | | | | | NEW |
| | Various | Immunology & Inflammation |  | [Progress bar] | | | | | |
| | Various | Metabolic – Diabetes (type 2/1) |  | [Progress bar] | | | | | |
| | Various | Metabolic – Diabetes (type 2/1) |  | [Progress bar] | | | | | |
| | Various | Nephrology |  | [Progress bar] | | | | | |
| | Various | Metabolic – Diabetes |  | [Progress bar] | | | | | |
| | Various | CNS – Alzheimer's disease |  | [Progress bar] | | | | | |
| | Various | Oncology – Immunotherapy |  | [Progress bar] | | | | | |
| | Various | Immunology & Inflammation – Tissue fibrosis |  | [Progress bar] | | | | | |
| | Various | CNS – Multiple Sclerosis | NEU ²⁾ | [Progress bar] | | | | | |
| | Various | Metabolic – Diabetes | >5 further programmes | [Progress bar] | | | | | |
| | Various | CNS | >5 further programmes | [Progress bar] | | | | | |
| | Various | Oncology | >10 further programmes | [Progress bar] | | | | | |
| | Various | CNS – Pain & Inflammation | >5 further programmes | [Progress bar] | | | | | |

¹⁾ EVT302 and EVT100: Evotec has regained the licence rights and is currently assessing potential business opportunities

²⁾ Not disclosed

First-in-class and best-in-class approaches – New paths of sourcing innovation

EVT Innovate – Strategy highlights



- New multi-target alliance with Bayer in kidney diseases
- First research collaboration under French Academic Bridge with Inserm in oncology
- Acceleration of TargetNASH
- Partnership with *ex scientia* to develop bispecific small molecule therapeutics
- Company formation of Topas Therapeutics
- Participation in Series A funding of Carrick Therapeutics
- **Expansion of network with Academia – LAB282: BRIDGE partnership with Oxford University, OSI and OUI (after period-end)**

New treatments to fight kidney diseases

Bayer & Evotec in CKD – Since 2016

Mission

- Evotec and Bayer develop novel and highly innovative therapeutics in the field of kidney diseases such as chronic kidney disease (“CKD”) in diabetes patients

Background¹⁾

- CKD is a huge unmet medical need – \$ 35 bn annual Medicare costs
- >10% of population worldwide is affected by CKD
- >2 million people worldwide currently receive dialysis treatments or a kidney transplant
- Alliance includes assets discovered within Evotec’s *CureNephron* initiative

Agreement with Bayer

- Minimum of **€ 14 m** including **research payments** and an undisclosed licence fee
- Potential pre-clinical, clinical and sales **milestone payments of potentially over € 300 m**; tiered royalties of up to a low double-digit percentage of net sales
- Integrated collaboration with substantial efforts from both partners
- Strategic **five-year** collaboration



From Academia to transformative projects


Evotec's academic network continues to grow

- Carefully select projects in indications of high unmet medical need
- Dramatically reduce “search costs” for capital
- Advance projects to tangible value inflection points, i.e. licensing or spin-offs
- Put experienced “drug hunting” teams/projects together right from the start



EVT BRIDGE addresses challenges of innovation


EVT BRIDGE value proposition



- Eliminating invalid data points right from the start
- Accelerating slow academic scouting and research funding processes
- Translating leading science into drug discovery work plans
- Eliminate search costs for initial “pre-seed” work plan

Oxford BRIDGE “LAB282” is the first larger scale implementation of a BRIDGE fund

Partnership between Oxford University, OSI, OUI and Evotec



¹⁾ Oxford Sciences Innovation

²⁾ £ 13 m

³⁾ Oxford University Innovation Ltd

⁴⁾ Proof of Concept


More than 10 projects primed for partnering

EVT Innovate – Cure X/Target X

| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |
|--|--|---|--|---|---|
| CureBeta ✓ (Harvard Stem Cell Institute) | CureNephron ✓ (Harvard, BWH, USC, AstraZeneca, Bayer) TargetASIC ✓ (BMBF/undisclosed Pharma partner) Somatoprim ✓ (Cortendo) TargetPicV (Haplogen) TargetFibrosis ✓ (Pfizer) | TargetImmuniT ✓ (Apeiron/Sanofi) TargetDBR (Yale) TargetMB ✓ (Second Genome) TargetPGB (Harvard) TargetKDM (Dana-Farber, Belfer) TargetIDX ✓ (Debiopharm) CureMN (Harvard) TargetEEM (Harvard) TargetAD ✓ (NBB/J&J) | TargetBCD ✓ (Sanofi) TargetDR (Internal) TargetATD (Internal) TargetFX (Internal) TargetKX (undisclosed) TargetCytokine (DRFZ/BMBF) Various (Fraunhofer Institute) | TargetFRX (Internal) TargetNTR (Internal) TargetKras (OSU) Various (Gladstone Institutes) ... | TargetaSN (MJFF) TargetBispecifics (<i>ex scientia</i>) TargetRhoB (Inserm) TargetNASH (Ellersbrook/Internal) ... |

Efficient approaches for participation in first-in-class innovation

Strategic rationale & examples for Evotec's innovation acceleration




Accelerating innovation on EVT platform

- Spin off valuable platforms outside of Evotec's main areas of interest for potential broader/ later stage applications
- Participate in financing rounds of promising companies, built on EVT platforms, via strategic investments
- Company formations with the aim of developing assets to next value inflection points

Outlook 2016

EVT Innovate – Expected key milestones 2016

- New clinical initiations and good progress of clinical pipeline within partnerships 

- Expansion of network of top-class academic alliances 

- Partnering of Cure X/Target X initiatives 

- Strong focus on iPSC (induced pluripotent stem cells) platform


Agenda

Highlights 9M 2016

EVT Execute

EVT Innovate

Financial performance and outlook



Significantly increased EBITDA

Key financials 9M 2016: Condensed income statement (IFRS)

in € m*

| | YTD 2015 | YTD 2016 | % vs. 2015 |
|---|-------------|---------------|------------|
| Revenues | 88.2 | 120.6 | 37% |
| Gross margin | 27.2% | 38.5% | – |
| • R&D expenses | (13.5) | (12.8) | (5)% |
| • SG&A expenses | (19.0) | (17.8) | (7)% |
| • Impairment of intangible assets | (0.1) | (1.4) | – |
| • Income from bargain purchase | 18.5 | – | – |
| • Other op. income (expenses), net | 2.4 | 6.0 | – |
| Operating income | 12.3 | 20.4 | 66% |
| Adjusted Group EBITDA¹⁾ | 3.4 | 30.6 | – |
| Net income | 10.7 | 11.4 | 7% |

- Revenue growth mainly due to an increase in base revenues, full 9 months Sanofi contribution and milestone achievements
- Gross margin increase due to milestones, Sanofi collaboration and higher base margin
- Decrease in SG&A due to one-off M&A and related costs in 2015
- € 1.4 m for full impairment of EVT100 in 2016
- Bargain purchase of € 18.5 m in 2015
- R&D tax credits in UK and France (€ 2.9 m increase)

Strong performance from both segments

Condensed income statement based on segments for 9M 2016

in € m*

| | EVT Execute | EVT Innovate | Inter- segment elimination | Evotec Group |
|-------------------------------------|------------------------|-------------------------|---|-------------------------|
| Revenues | 126.6 | 17.9 | (23.9) | 120.6 |
| Gross margin | 32.9% | 45.6% | – | 38.5% |
| • R&D expenses | (0.0) | (16.3) | 3.5 | (12.8) |
| • SG&A expenses | (13.9) | (3.9) | – | (17.8) |
| • Impairment of intangible assets | – | (1.4) | – | (1.4) |
| • Other op. income (expenses), net | 5.3 | 0.7 | – | 6.0 |
| Operating income (loss) | 33.1 | (12.7) | – | 20.4 |
| Adjusted EBITDA¹⁾ | 41.3 | (10.7) | – | 30.6 |

- Strong base business and milestone achievements
- R&D expenses on similar level as in prior-year period
- Significantly improved adjusted EBITDA of EVT Execute compared to 9M 2015 (€ 16.1 m)
- Strong gross margin in EVT Innovate

Strong gross margin

Key financials Q3 2016: Condensed income statement (IFRS)


in € m

| | Q3 2015 | Q3 2016 | Q3 2016 gross margin improved by milestone achievements and improved capacity utilisation |
|---|--------------|--------------|---|
| Revenues | 33.2 | 45.2 | |
| Gross margin | 29.2% | 45.1% | |
| • R&D expenses | (5.0) | (3.8) | |
| • SG&A expenses | (6.7) | (6.0) | |
| • Other op. income (expenses), net | 1.3 | 1.4 | |
| Operating income (loss) | (0.6) | 12.0 | |
| Adjusted Group EBITDA¹⁾ | 2.6 | 14.8 | |
| Net income (loss) | (2.9) | 8.7 | |


Business grows and with improved gross margin

Revenues & gross margin trend 9M 2016

Continued significant growth of Group revenues¹⁾ (in € m)



Growth in base business, improved capacity utilisation and milestone achievements (in %)



¹⁾ In the first nine months of 2016, Sanofi contributed revenues of € 38.5 m. Excluding the Sanofi contribution, Evotec Group revenues increased by 29% compared to the prior-year period.

²⁾ From 01 January 2016 onwards, amortisation of intangible assets are no longer presented in a separate line in the consolidated income statement but are allocated to the relating cost lines in the income statement. The 2014 and 2015 figures were changed accordingly.

Strong 2016, strong visibility and outlook for 2017

Expected key milestones 2016

EVT Execute

- New long-term deals with large and mid-sized Pharma
- Expansion of foundations and biotech network in USA/EU
- New performance-based integrated technology/disease alliance
- Milestones from existing alliances



EVT Innovate

- New clinical initiations and good progress of clinical pipeline within partnerships
- Expansion of network of top-class academic alliances
- Partnering of Cure X/Target X initiatives
- Strong focus on iPSC (induced pluripotent stem cells) platform



Important next dates

Financial Calendar 2017

| | |
|--------------------------------------|------------------|
| Annual Report 2016 | 28 March 2017 |
| Quarterly Statement Q1 2017 | 10 May 2017 |
| Annual General Meeting 2017 | 14 June 2017 |
| Half-year 2017 Interim Report | 10 August 2017 |
| Quarterly Statement 9M 2017 | 08 November 2017 |

QUESTIONS
AND ANSWERS

